• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by BiomX Inc.

    11/13/24 5:14:46 PM ET
    $PHGE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PHGE alert in real time by email
    SC 13G/A 1 tm2428335d1_sc13ga.htm SC 13G/A

     

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    SCHEDULE 13G

     

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

     

    (Amendment No.  1)*

     

    BiomX Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    09090D301

    (CUSIP Number)

     

    AMR Action Fund, L.P.
    c/o AMR Action Fund GP, LLC

    225 Franklin Street, Suite 1750
    Boston, MA 02110
    Tel 862-325-3580

     

    With a copy to:

     

    Derek Stoldt

    Arnold & Porter Kaye Scholer LLP

    250 West 55th Street

    New York, NY 10019

    Tel 212-836-8000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    September 30, 2024

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ¨ Rule 13d-1(b)

     

      x Rule 13d-1(c)

     

      ¨ Rule 13d-1(d)

     

      * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 09090D301 13G Page 2 of 10 Pages

    1.

    NAMES OF REPORTING PERSON

     

    AMR Action Fund, L.P.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (See Instructions)

     

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    876,888(1)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    876,888(1)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    876,888(1)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.9%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (1) The number of shares of Common Stock beneficially owned by the Reporting Person does not include an aggregate of (i) 3,662,300 shares of Common Stock underlying 36,623 shares of Series X Preferred Stock convertible into Common Stock (subject to a beneficial ownership limitation) and (ii) 1,514,566 shares of Common Stock underlying warrants exercisable for Common Stock (subject to a beneficial ownership limitation).

     

     

     

     

    CUSIP No. 09090D301 13G Page 3 of 10 Pages

    1.

    NAMES OF REPORTING PERSON

     

    AMR Action Fund GP, LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

     

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER


    876,888(2)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER


    876,888(2)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    876,888(2)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.9%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (2) Consists of shares of Common Stock held by AMR Action Fund, L.P. See Footnote 1.

     

     

     

     

    CUSIP No. 09090D301 13G Page 4 of 10 Pages

    1.

    NAMES OF REPORTING PERSON

     

    AMR Action Fund, SCSp

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

     

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER


    876,888(3)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER


    876,888(3)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    876,888(3)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.9%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    PN

     

    (3) The number of shares of Common Stock beneficially owned by the Reporting Person does not include an aggregate of (i) 3,662,300 shares of Common Stock underlying 36,623 shares of Series X Preferred Stock convertible into Common Stock (subject to a beneficial ownership limitation) and (ii) 1,514,566 shares of Common Stock underlying warrants exercisable for Common Stock (subject to a beneficial ownership limitation).

     

     

     

     

    CUSIP No. 09090D301 13G Page 5 of 10 Pages

    1.

    NAMES OF REPORTING PERSON

     

    AMR Action Fund GP, S.a.r.l.

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (See Instructions)

     

    (a) ¨

    (b) x

    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Luxembourg

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER


    876,888(4)

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER


    876,888(4)

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    876,888(4)

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    (see instructions)

     

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.9%

    12.

    TYPE OF REPORTING PERSON (see instructions)

     

    OO

     

    (4) Consists of shares of Common Stock held by AMR Action Fund, SCSp. See Footnote 3.

     

     

     

     

    Item 1.

     

    (a)

    Name of Issuer

    BiomX Inc.

       
    (b)

    Address of Issuer’s Principal Executive Offices
    708 Quince Orchard Rd, Suite 205

    Gaithersburg, MD 20878

     

    Item 2.

     

    (a) Name of Person Filing:

     

    This Amendment is being filed by each of:

     

    (i) AMR Action Fund, L.P.;

     

    (ii) AMR Action Fund GP, LLC;

     

    (iii) AMR Action Fund, SCSp; and

     

    (iv) AMR Action Fund GP, S.a.r.l.

     

    (each a “Reporting Person” and, collectively, the “Reporting Persons”).

     

    (b)

    Address of Principal Business Office or, if None, Residence:

     

    The principal business office of each of the Reporting Persons are:

     

    AMR Action Fund, L.P., c/o AMR Action Fund GP, LLC, 225 Franklin Street, Suite 1750, Boston, MA 02110

    AMR Action Fund GP, LLC, 225 Franklin Street, Suite 1750, Boston, MA 02110

    AMR Action Fund, SCSp, c/o AMR Action Fund GP, S.a.r.l., 16 Rue Eugene Ruppert, L-2543 Luxembourg, Grand Duchy of Luxembourg

    AMR Action Fund GP, S.a.r.l., 16 Rue Eugene Ruppert, L-2543 Luxembourg, Grand Duchy of Luxembourg

     

    (c)

    Citizenship:


    AMR Action Fund GP, S.a.r.l., and AMR Action Fund, SCSp are organized under the laws of Luxembourg. AMR Action Fund GP, LLC and AMR Action Fund, L.P. are organized under the laws of the State of Delaware.

       
    (d)

    Title of Class of Securities

     

    Common Stock, par value $0.0001 per share (the “Shares”)

       
    (e)

    CUSIP Number

     

    09090D301

     

     

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
         
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
         
    (e) ¨ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ¨ A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
         
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ¨ A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);
         
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________

     

    Not applicable.

     

    Item 4. Ownership.

     

    Item 4 is hereby amended in its entirety as follows:

     

    (a) (b) Number and percentage of Issuer Shares beneficially owned by each Reporting Person:

     

    Reporting Person  Number of Shares   Percentage of Class 
    AMR Action Fund, L.P.   876,888    4.9%
    AMR Action Fund GP, LLC   

    876,888

        

    4.9

    %
    AMR Action Fund, SCSp   876,888    4.9%
    AMR Action Fund GP, S.a.r.l.   

    876,888

        

    4.9

    %

     

    With respect to each of the Reporting Persons:

     

    (a) Number of shares as to which the Reporting Person has:
         
      (i)

    Sole power to vote or to direct the vote:

    AMR Action Fund, L.P.: 0

    AMR Action Fund GP, LLC: 0

    AMR Action Fund, SCSp: 0

    AMR Action Fund GP, S.a.r.l.: 0

     

     

     

     

      (ii)

    Shared power to vote or to direct the vote:

    AMR Action Fund, L.P.: 876,888

    AMR Action Fund GP, LLC: 876,888

    AMR Action Fund, SCSp: 876,888

    AMR Action Fund GP, S.a.r.l.: 876,888

         
      (iii)

    Sole power to dispose or to direct the disposition of:

    AMR Action Fund, L.P.: 0

    AMR Action Fund GP, LLC: 0

    AMR Action Fund, SCSp: 0

    AMR Action Fund GP, S.a.r.l.: 0

         
      (iv)

    Shared power to dispose or to direct the disposition of:

    AMR Action Fund, L.P.: 876,888

    AMR Action Fund GP, LLC: 876,888

    AMR Action Fund, SCSp: 876,888

    AMR Action Fund GP, S.a.r.l.: 876,888

     

    The information as of the date of the event which requires filing of this statement required by Items 4(a) - (c) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each such Reporting Person. AMR Action Fund, L.P. is the record owner of 650,997 shares of Common Stock. AMR Action Fund GP, LLC is the general partner of AMR Action Fund, L.P. and may be deemed to have voting and dispositive control over the shares of Common Stock held by AMR Action Fund, L.P. AMR Action Fund, SCSp is the record owner of 225,891 shares of Common Stock. AMR Action Fund GP, S.a.r.l. is the general partner of AMR Action Fund, SCSp and may be deemed to have voting and dispositive control over the shares of Common Stock held by AMR Action Fund, SCSp. Each of AMR Action Fund GP, LLC and AMR Action Fund GP, S.a.r.l. disclaims beneficial ownership of the shares of Common Stock.

     

    Throughout this report, the percentage of outstanding shares of Common Stock beneficially owned by the Reporting Persons reflects 17,895,845 shares of Common Stock as of August 12, 2024, based on the Issuer’s Quarterly Report on Form 10-Q, filed with the U.S. Securities and Exchange Commission on August 14, 2024, and the Issuer’s 1-for-10 reverse stock split effective as of August 26, 2024, as reported in the Issuer’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission on August 16, 2024.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

     

    Item 10. Certification.

     

    Each of the Reporting Persons hereby certifies as follows:

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the Issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    Dated: November 13, 2024

     

    AMR ACTION FUND, L.P.

     

    By: AMR Action Fund GP, LLC, its General Partner

     

    /s/ Henry Skinner  
    Name:  Henry Skinner  
    Title: Chief Executive Officer  

     

    AMR ACTION FUND GP, LLC

     

    /s/ Henry Skinner  
    Name:  Henry Skinner  
    Title: Chief Executive Officer  

     

    AMR ACTION FUND, SCSp

     

    By: AMR Action Fund GP, S.a.r.l., its General Partner

     

    /s/ Henry Skinner  
    Name:  Henry Skinner  
    Title: Class A Manager  

     

    AMR ACTION FUND GP, S.a.r.l.

     

    /s/ Henry Skinner  
    Name:  Henry Skinner  
    Title: Class A Manager  

     

     

     

     

    EXHIBIT INDEX

     

    Exhibit    
    99.1   Joint Filing Agreement (incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by AMR Action Fund, L.P., on March 25, 2024).

     

     

     

    Get the next $PHGE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHGE

    DatePrice TargetRatingAnalyst
    11/16/2021$16.00 → $13.00Buy
    Chardan Capital
    10/19/2021$28.00 → $16.00Buy
    Chardan Capital
    10/18/2021$20.00 → $10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $PHGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $13.00 from $16.00 previously

      11/16/21 9:23:03 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Chardan Capital reiterated coverage on BiomX with a new price target

      Chardan Capital reiterated coverage of BiomX with a rating of Buy and set a new price target of $16.00 from $28.00 previously

      10/19/21 8:36:54 AM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on BiomX with a new price target

      HC Wainwright & Co. reiterated coverage of BiomX with a rating of Buy and set a new price target of $10.00 from $20.00 previously

      10/18/21 12:27:44 PM ET
      $PHGE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care